{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihpt4gvsx7minkmdo54carhvpirv5rsyl4id3atbfmendfk5i7csa",
    "uri": "at://did:plc:o7x3aaueo7gbdj5s6ywwl7sl/app.bsky.feed.post/3mjte5muaqgt2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia4kzoza6vodhtkuzrg2ozffn6ngxsqqkfbtxo5b557qb7xn6k454"
    },
    "mimeType": "image/jpeg",
    "size": 84025
  },
  "path": "/trump-signs-executive-order-to-fast-track-psychedelic-drug-reviews-commits-50-million-for-ibogaine-research/?utm_source=rss&utm_medium=rss&utm_campaign=trump-signs-executive-order-to-fast-track-psychedelic-drug-reviews-commits-50-million-for-ibogaine-research",
  "publishedAt": "2026-04-18T14:48:39.000Z",
  "site": "https://thedeepdive.ca",
  "tags": [
    "Latest",
    "Psychedelics",
    "Ibogaine",
    "Trump Signs Executive Order to Fast-Track Psychedelic Drug Reviews, Commits $50 Million For Ibogaine Research",
    "the deep dive"
  ],
  "textContent": "US President Donald Trump has signed an executive order to expedite the FDA review process for certain psychedelic drugs, with a particular focus on ibogaine, a compound eyed for treating post-traumatic stress disorder and addiction. Alongside this, the administration announced a $50 million federal investment to advance research into ibogaine’s potential, especially for veterans grappling […]\n\nThe post Trump Signs Executive Order to Fast-Track Psychedelic Drug Reviews, Commits $50 Million For Ibogaine Research appeared first on the deep dive.",
  "title": "Trump Signs Executive Order to Fast-Track Psychedelic Drug Reviews, Commits $50 Million For Ibogaine Research"
}